It is likely that AURKA exerts similarly deleterious effects in MYCN-driven MB, with evidence for this provided by significantly decreased tumour volumes, and a tendency towards increased survival in Ptch1+/-;p53-/- mice treated with the AURKA inhibitor CD535 (109). The gene discussed is MYCN; the disease is neoplasm.